Lumenis® Announces Research, Development and Licensing Agreement with Wellman Center for Photomedicine

Share Article

Fostering new indications for Lumenis’ UltraPulse CO2 laser platform

Lumenis Ltd. the world's largest medical laser company and a global developer, manufacturer and seller of laser and light-based devices for aesthetic, ophthalmic, and surgical applications, announced today that it has entered into a joint research, development and licensing agreement with Wellman Center for Photomedicine at Massachusetts General Hospital, the world's largest academic research facility dedicated to light-based biomedical research.

Despite recent developments in dermatology, there are many indications yet to be explored. The goal of the partnership is to develop new treatments that will progress the field by expanding indications and improving patient outcomes.

"This partnership aligns two great leaders in the field of laser dermatology," said Robert Mann, Senior VP and General Manager, Global Aesthetic and Dermatology for Lumenis. “Together we are in a stronger position to innovate more quickly, foster new indications based on our unique UltraPulse CO2 platform, the highest performing ablative platform in industry, and advance this field in new directions.”
Dr. Dieter Manstein, physician and physicist with Wellman, was the lead creator and co-inventor of fractional laser technology and has advanced hair removal and many other dermatology innovations. Much of Dr. Manstein’s work utilizes Lumenis’ UltraPulse CO2 technology, widely accepted as a standard of care for fractional dermatologic procedures.

“We are very excited to engage in a significant translational research and development agreement with Lumenis,” said Dr. Manstein. "This partnership creates a great opportunity to allow our teams to accelerate innovation, explore new and exciting indications, and ultimately improve patient care. The unique specifications of the UltraPulse system provides us with opportunities not available with typical systems."

"This partnership with Wellman Center for Photomedicine is particularly exciting for Lumenis because it is a continuation of a legacy," said Dov Ofer, President and CEO of Lumenis. “Wellman was pivotal in the validation of the UltraPulse CO2 laser for skin resurfacing during its inception in the 1990s.

About Lumenis
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 100 FDA clearances, an installed base of over 80,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit:

For further information contact:
Michelle Maydan
Director of Corporate Communications
e-mail: mmaydan(at)lumenis(dot)com

Lumenis®, its logo, and UltraPulse are trademarks or registered trademarks of Lumenis and its affiliated companies.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Maydan
Lumenis, LTD
Email >
Visit website